biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > New Questions

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Jun 09, 2023 4:09pm

247 Views

Post# 35489200

RE:RE:RE:RE:RE:RE:New Questions

Feed them before you try and cure them in 10 years with science that may never work. Preclinical biotech is a luxury in difficult times and populist politicians are destabilizing governments as they exploit difficult times.

"A new report says reliance on food banks and other food charities is expected to increase by 60 per cent in 2023, following a 134 per cent growth of food program dependency in 2022." Food banks brace for 60 per cent increase in demand in 2023 | CTV News

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale